Last edition
News about Drug Discovery & Development
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
Drug Discovery & Development | 19/01/2026 | By News Bureau | 257
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Drug Discovery & Development | 19/01/2026 | By News Bureau | 320
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Drug Discovery & Development | 19/01/2026 | By News Bureau | 305
Russian Scientists Develop Chemical Method to Boost Anti-Cancer Drug Potency
Researchers in Russia have developed a novel chemical method that could significantly enhance the effectiveness of anti-cancer medicines, offering new momentum to oncology drug development.
Drug Discovery & Development | 16/01/2026 | By Darshana | 226
US FDA Delays Two Drug Reviews Under New Priority Voucher Program
The U.S. Food and Drug Administration (FDA) has delayed the review of two medicines selected under its recently launched Commissioner’s National Priority Voucher Program, after regulators raised concerns related to safety and clinical effectiveness.
Drug Discovery & Development | 16/01/2026 | By Darshana | 424
J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study
Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.
Drug Discovery & Development | 15/01/2026 | By News Bureau | 163
European Commission Approves Teizeild to Delay Onset of Type 1 Diabetes
Teizeild (teplizumab) becomes the first disease-modifying therapy approved in the EU to delay progression to stage III type 1 diabetes in eligible adults and children aged eight and above.
Drug Discovery & Development | 13/01/2026 | By News Bureau | 283
Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer
Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.
Drug Discovery & Development | 12/01/2026 | By News Bureau | 359
Nona Biosciences, Link Cell Therapies Partner to Advance Next-Gen CAR-T Antibody Discovery
The multi-target collaboration will combine Nona Biosciences’ fully human HCAb Harbour Mice and NonaCarFx platforms with Link Cell Therapies’ cell therapy expertise to develop novel CAR-T candidates for solid and hematologic cancers.
Drug Discovery & Development | 12/01/2026 | By News Bureau | 231
Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration
The partnership between Pierre Fabre and Iktos integrates generative AI and automated chemistry to accelerate small-molecule cancer drug development.
Drug Discovery & Development | 09/01/2026 | By News Bureau | 317
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy